Envestnet Asset Management Inc. Boosts Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Envestnet Asset Management Inc. grew its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 9.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 301,339 shares of the medical instruments supplier’s stock after buying an additional 26,947 shares during the quarter. Envestnet Asset Management Inc. owned 0.42% of West Pharmaceutical Services worth $99,258,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Avantax Advisory Services Inc. acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at about $288,000. ING Groep NV raised its stake in shares of West Pharmaceutical Services by 5.8% during the fourth quarter. ING Groep NV now owns 10,129 shares of the medical instruments supplier’s stock valued at $3,567,000 after purchasing an additional 556 shares during the period. Norges Bank acquired a new position in shares of West Pharmaceutical Services during the fourth quarter worth $300,250,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of West Pharmaceutical Services in the fourth quarter valued at $1,062,000. Finally, UBS Group AG grew its holdings in West Pharmaceutical Services by 15.8% during the 4th quarter. UBS Group AG now owns 82,290 shares of the medical instruments supplier’s stock valued at $28,976,000 after purchasing an additional 11,245 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insider Activity

In related news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $295.86 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The company’s fifty day moving average price is $304.81 and its two-hundred day moving average price is $338.60. The firm has a market capitalization of $21.55 billion, a P/E ratio of 39.03, a P/E/G ratio of 10.61 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. During the same quarter last year, the firm posted $2.11 EPS. The company’s revenue was down 6.9% compared to the same quarter last year. On average, research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.